{
    "organizations": [],
    "uuid": "0b4f921ec5b6e9fcaabb940eb4ab511207a124fc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alkermes-receives-refusal-to-file/brief-alkermes-receives-refusal-to-file-letter-from-fda-for-alks-5461-idUSFWN1RF062",
    "ord_in_thread": 0,
    "title": "BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2, 2018 / 11:05 AM / in 16 minutes BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461 Reuters Staff \nApril 2 (Reuters) - Alkermes Plc: \n* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461 \n* ALKERMES PLC SAYS “STRONGLY DISAGREES WITH FDA’S CONCLUSIONS AND PLANS TO APPEAL FDA’S DECISION” \n* UPON ITS PRELIMINARY REVIEW, FDA HAS TAKEN POSITION THAT IT IS UNABLE TO COMPLETE A SUBSTANTIVE REVIEW OF REGULATORY PACKAGE \n* ‍FDA REQUESTED CONDUCT OF BIOAVAILABILITY STUDY TO GENERATE ADDITIONAL BRIDGING DATA BETWEEN ALKS 5461 & REFERENCE LISTED DRUG, BUPRENORPHINE​ \n* INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA TO DETERMINE NEXT STEPS REQUIRED TO RESUBMIT NDA \n* ISSUED FINANCIAL GUIDANCE FOR 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-02T14:05:00.000+03:00",
    "crawled": "2018-04-02T14:26:42.019+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "minute",
        "receives",
        "refusal",
        "file",
        "letter",
        "fda",
        "alks",
        "reuters",
        "staff",
        "april",
        "reuters",
        "alkermes",
        "plc",
        "alkermes",
        "receives",
        "refusal",
        "file",
        "letter",
        "fda",
        "alks",
        "alkermes",
        "plc",
        "say",
        "strongly",
        "disagrees",
        "fda",
        "conclusion",
        "plan",
        "appeal",
        "fda",
        "decision",
        "upon",
        "preliminary",
        "review",
        "fda",
        "taken",
        "position",
        "unable",
        "complete",
        "substantive",
        "review",
        "regulatory",
        "package",
        "requested",
        "conduct",
        "bioavailability",
        "study",
        "generate",
        "additional",
        "bridging",
        "data",
        "alks",
        "reference",
        "listed",
        "drug",
        "intends",
        "seek",
        "immediate",
        "guidance",
        "including",
        "requesting",
        "type",
        "meeting",
        "fda",
        "determine",
        "next",
        "step",
        "required",
        "resubmit",
        "nda",
        "issued",
        "financial",
        "guidance",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}